Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

novo nordisk pharma ag - insulinum detemirum - injektionslösung - insulinum detemirum 100 u., natrii chloridum, zincum, glycerolum, natrii phosphates, conserv.: metacresolum 2.06 mg, phenolum 1.8 mg, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - diabetes mellitus - biotechnologika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

novo nordisk pharma ag - insulinum detemirum - injektionslösung - insulinum detemirum 100 u., natrii chloridum, zincum, glycerolum, natrii phosphates, conserv.: metacresolum 2.06 mg, phenolum 1.8 mg, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - diabetes mellitus - biotechnologika

Europäische Union - Deutsch - EMA (European Medicines Agency)

mirum pharmaceuticals international b.v. - maralixibat chloride - alagille syndrome - other drugs for bile therapy - livmarli is indicated for the treatment of cholestatic pruritus in patients with alagille syndrome (algs) 2 months of age and older.

Österreich - Deutsch - AGES (Agentur für Gesundheit und Ernährungssicherheit)

pfizer corporation austria gmbh - vincristin sulfat - vincristin

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

biologische heilmittel heel gmbh - serum ovis (pot.-angaben) - flüssige verdünnung zur injektion - serum ovis (pot.-angaben) 1.1ml

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

biologische heilmittel heel gmbh - serum ovis (pot.-angaben), serum ovis (pot.-angaben), serum ovis (pot.-angaben), serum ovis (pot.-angaben) - flüssige verdünnung zur injektion - serum ovis (pot.-angaben) 0.275ml; serum ovis (pot.-angaben) 0.275ml; serum ovis (pot.-angaben) 0.275ml; serum ovis (pot.-angaben) 0.275ml

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

biologische heilmittel heel gmbh - serum ovis (pot.-angaben), serum ovis (pot.-angaben), serum ovis (pot.-angaben) - flüssige verdünnung zur injektion - serum ovis (pot.-angaben) 0.367ml; serum ovis (pot.-angaben) 0.367ml; serum ovis (pot.-angaben) 0.367ml

Europäische Union - Deutsch - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - vorläuferzelle lymphoblastische leukämie-lymphom - antineoplastische mittel - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

boiron sa - serum de yersin ex oryctolagus cuniculatus c6 (ph.eur.hom. 3.1.3) - granules - l'autorisation est également valide pour toutes les dilutions supérieures subséquentes: serum de yersin ex oryctolagus cuniculatus c6 (ph.eur.hom. 3.1.3) 0.01 g, saccharum 0.85 g, lactosum 0.15 g, ad globulos pro 1 g corresp. 20 granula homoeopathica imbuta. - autorisation avec dossier restreint sans indication selon l’art. 25, al. 1 oamédcophy (rs 812.212.24) - homöopathische arzneimittel

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

boiron sa - serum anticolibacillaire ex oryctolagus cuniculatus c6 (ph.eur.hom. 3.1.3) - granules - l'autorisation est également valide pour toutes les dilutions supérieures subséquentes: serum anticolibacillaire ex oryctolagus cuniculatus c6 (ph.eur.hom. 3.1.3) 0.01 g, saccharum 0.85 g, lactosum 0.15 g, ad globulos pro 1 g corresp. 20 granula homoeopathica imbuta. - autorisation avec dossier restreint sans indication selon l’art. 25, al. 1 oamédcophy (rs 812.212.24) - homöopathische arzneimittel